Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
VentriPoint Diagnostics Ltd. is a medical technology company focused on the development and commercialization of advanced cardiac imaging software. The company operates within the medical devices and diagnostic imaging industries, with a specific emphasis on cardiology. VentriPoint’s core product is VMS+, a software platform designed to provide accurate three-dimensional measurements of right ventricular (RV) size and function using standard two-dimensional echocardiography data, addressing a long-standing clinical challenge in cardiac imaging.
The company’s primary revenue driver is the licensing and sale of VMS+ software to hospitals, cardiology clinics, and research institutions. VentriPoint targets clinicians involved in the diagnosis and management of congenital heart disease, pulmonary hypertension, and other conditions where right ventricular assessment is critical. Founded in 2003, the company originated as a university-linked research initiative and has evolved into a publicly listed entity on the TSX Venture Exchange under the symbol VPT.V, focusing on regulatory approvals, clinical validation, and early-stage commercialization.
Business Operations
VentriPoint operates primarily as a software-focused medical device company. Its main operating activity is the development, regulatory clearance, and commercialization of VMS+, which integrates proprietary algorithms and a validated database of cardiac magnetic resonance imaging (MRI) data to reconstruct accurate 3D RV models from conventional ultrasound inputs. Revenue is generated through software licenses, maintenance agreements, and clinical or research deployments.
The company conducts its operations primarily in Canada and the United States, with additional clinical and academic users in Europe and other international markets. VentriPoint does not operate manufacturing facilities, as its core asset is intellectual property rather than physical hardware. The company has historically collaborated with academic hospitals, clinical research centers, and echocardiography system providers, though publicly disclosed long-term joint ventures or material subsidiaries have not been consistently identified in available filings.
Strategic Position & Investments
VentriPoint’s strategic direction centers on expanding clinical adoption of VMS+ by obtaining regulatory clearances, increasing clinician awareness, and validating clinical utility through peer-reviewed studies. The company positions itself as a differentiated solution provider by addressing the right ventricle, an area where conventional echocardiography has recognized limitations and where MRI, the reference standard, is costly and less accessible.
The company has historically invested in clinical trials, regulatory submissions, and software enhancements rather than acquisitions. Public disclosures do not indicate material acquisitions or a diversified portfolio of subsidiaries. VentriPoint’s technology is aligned with broader trends in non-invasive diagnostics, AI-assisted medical imaging, and cost-effective alternatives to MRI, although the extent of commercialization and market penetration remains dependent on adoption rates and reimbursement pathways.
Geographic Footprint
VentriPoint is headquartered in Canada, with its corporate operations centered in Edmonton, Alberta. The company’s primary commercial and regulatory focus has been on North America, particularly the United States, which represents the largest addressable market for advanced cardiac imaging software.
Internationally, VentriPoint has reported usage of its technology in select clinical and research settings across Europe and other regions. However, its global footprint remains limited compared to large medical device companies, reflecting its status as an early-stage commercial enterprise. International influence is primarily driven by academic collaborations and regulatory progress rather than large-scale direct operations.
Leadership & Governance
VentriPoint is led by an executive team with experience in medical technology, cardiology-focused product development, and public company governance. The company was founded by individuals with academic and clinical research backgrounds, reflecting its origins in applied medical research and translational science. Leadership has emphasized clinical validation, regulatory credibility, and disciplined capital management as central elements of its strategy.
Key executives include:
- Hugh MacNaught – President and Chief Executive Officer
- Mike LeBlanc – Chief Financial Officer
- Andrew Jamieson – Vice President, Product Development
- Dr. Bob S. Hamilton – Medical Director
The board and management team collectively promote a strategy centered on evidence-based adoption, long-term clinical relevance, and cautious scaling within regulated healthcare markets.